About 23.6 million, or 8 percent of people in the United States, have diabetes, and approximately 90 to 95 percent of people diagnosed with diabetes have type 2 diabetes.  The ADA and the American College of Cardiology emphasize that it is critical to reduce both A1C and LDL cholesterol levels, as more than 50 percent of adults with type 2 diabetes also have elevated LDL cholesterol, greatly increasing their risk of cardiovascular disease. The effect of Welchol on cardiovascular morbidity and mortality has not been determined.

"As the only medication approved to treat both A1C and LDL-C in adults with type 2 diabetes and primary hyperlipidemia, Welchol addresses both of these chronic health conditions and provides physicians with a unique therapeutic approach for the comorbid patient," said Jay M. Feingold, MD, PhD, Vice President of Medical Affairs at Daiichi Sankyo, Inc.   "We are encouraged by these study results, which reinforce the benefits of Welchol for treating adult patients with type 2 diabetes and/or elevated LDL cholesterol."

SOURCE Daiichi Sankyo